[Expression of a novel biomarker, MR-1S, in ovarian carcinoma and its biological significance].
OBJECTIVE
To investigate the expression of a novel biomarker, human short-type myofibrillogenesis regulator-1 (MR-1S), in ovarian carcinoma and explore its biological significance.


METHODS
The MR-1S mRNA levels were analyzed by reverse transcription polymerase chain reaction (RT-PCR) in 23 specimens of ovarian cancers and 20 specimens of control ovarian tissues. The expression of MR-1S in these specimens was detected by real-time PCR and immunohistochemical analysis. In addition, the expression of MR-1S in ovarian cancer SKOV3 cells was determined by immunocytochemisty. MR-1S mRNA and protein level of SKOV3 cells was compared in the two groups treated by carboplatin and paclitaxel at 24 h, 48 h and 72 h, respectively. Furthermore, the expression of MR-1S was analyzed in liner concentration range of the anti-cancer drug, and the potential relation between MR-1S expression and cell apoptosis rate was predicted.


RESULTS
The level of MR-1S mRNA was significantly higher in ovarian cancer tissues than those of control tissues by RT-PCR and Real-time PCR analysis. MR-1S protein was overexpressed in ovarian cancer tissues with a positive rate of 78.3% (18/23) than that in the control tissues (30.0%, P<0.05) through IHC analysis. The expression of MR-1S was markedly decreased by treatment with carboplatin and paclitaxel, and there was a direct correlation between MR-1S expression and apoptosis rate, especially in a liner concentration range of paclitaxel at 48 h.


CONCLUSIONS
MR-1S is highly expressed in ovarian cancer cells and tissues, and it may be a promising biomarker for diagnosis and a new target for ovarian cancer therapy.
Department of Clinical Laboratory, Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Ren-quan
RQ
Lu
Min
M
Sun
Xiang
X
Gao
Lin
L
Guo
D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D016190:Carboplatin / Q000494:pharmacology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008875:Middle Aged; D009124:Muscle Proteins / Q000235:genetics / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D055815:Young Adult
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D009124:Muscle Proteins; C495444:PNKD protein, human; D012333:RNA, Messenger; D016190:Carboplatin; D017239:Paclitaxel